How breakthrough designation for a new multiple myeloma drug helps three drug companies.
Check out which stocks one of the world's most successful hedge funds recently bought and why.
Big pharma's home to many great dividends, but is Bristol-Myers Squibb's yield the best bet for your money?
Cancer research as a team sport.
A quickly-soaring market valuation is hiding a realistic interpretation of Repligen's P/E ratio after the end of a royalty stream from Bristol-Myers Squibb.
Top stories in health care and biotech.
Three leading names take big hits on what turned out to be a horrid day for investors, as Bristol-Myers, National Bank of Greece, and Alliant Techsystems all fall in big ways
Celldex (CLDX) began as a subidiary of Bristol-Myers (BMY) Medarex. Here's what you need to know about their collaboration.
Celldex shares soar after it buddies up with this Big Pharma to explore various cancer treatment options in phase 1/2 studies.
Bristol-Myers Squibb's nivolumab and Merck's MK-3475 take center stage for the second year running.